Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
4TEEN4 Pharmaceuticals GmbH manages a portfolio in the Biotechnology & Pharmaceuticals sector with 4 pending office actions. These actions are distributed across 4 distinct examiners, showing that the workload is spread among multiple officials. The matters are currently being reviewed within 3 distinct art units, suggesting some diversity in the technical classification of their intellectual property.
KARUNASENA, ENUSHA is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action. While the total pending actions are 4, the involvement of 3 distinct art units indicates that the biotechnology filings are being reviewed by multiple specialized groups. No single official has a dominant influence over the company current prosecution.
This distribution of 4 pending office actions across 4 distinct examiners means that the company must navigate various individual examination styles. The presence of 3 distinct art units further suggests that the pending office actions cover a range of specific sub-technologies. Practitioners should prepare for varied feedback, as the distinct examiners may apply different interpretations of the Biotechnology & Pharmaceuticals guidelines.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KARUNASENA, ENUSHA | 1 | 0.0% | +0.0% |
| WEN, SHARON X | 1 | 56.9% | +32.6% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| CHEONG, CHEOM-GIL | 1 | 64.2% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | KARUNASENA, ENUSHA | — |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | WEN, SHARON X | 45d overdue |
| 17802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | AEDER, SEAN E | — |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| 1641 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | KARUNASENA, ENUSHA | 1645 | §112DP | Non-Final OA | — | Pending | Jun 21, 2023 |
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | WEN, SHARON X | 1641 | §103§112DP | Final Rejection | 45d overdue | Pending | Nov 10, 2022 |
| 17802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | AEDER, SEAN E | 1642 | §103Other | Final Rejection | — | Pending | Aug 26, 2022 |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | 1645 | §101 | Non-Final OA | — | Pending | Oct 22, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial